Canntab Therapeutics Limited (CSE:PILL.CN) (OTCMKTS:CTABF) CFO Richard Goldstein tells Proactive Investors the Canadian company has achieved a major milestone by receiving a cultivation license from Health Canada.
The license allows Canntab to cultivate industrial hemp, said Goldstein adding it intends to use the license to secure hemp biomass that it will use to extract CBD to manufacture cannabis hard pills.
Price: $0.60
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Canntab Therapeutics (CSE:PILL.CN-OTCQX: CTABF) Chief Financial Officer Richard Goldstein joined Steve Darling from Proactive Investors Vancouver on Skype with news that the company has received an initial assessment from the Geneva-based International Preliminary Report on Patentability...
Market Report
Industry & services
Health
Finance
Basic Materials
Prev article
